ArticleMolecular genetics and genomics : MGG2026
Genomic characterization of Pseudomonas aeruginosa infecting Abidjanvirus Lucjan.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Multidrug-resistant (MDR) Pseudomonas aeruginosa remains a major cause of hospital-acquired infections, and alternative antimicrobial strategies are urgently needed. Bacteriophages infecting P. aeruginosa are increasingly explored as adjuncts or alternatives to antibiotic therapy, yet many newly isolated phages remain incompletely characterized. Here, we report the genomic and functional characterization of bacteriophage Lucjan, a lytic virus infecting clinical isolates of P. aeruginosa. Whole-genome sequencing revealed a 59,433 bp double-stranded DNA genome with 63.7% GC content encoding 81 predicted open reading frames. Comparative genomics and VIRIDIC analysis established Lucjan as a novel species within the genus Abidjanvirus. No antibiotic resistance genes, virulence factors, or canonical lysogeny-associated modules were detected. Lifestyle prediction and genomic architecture, including a canonical holin-endolysin cassette, support a lytic infection strategy. Biological characterization demonstrated adsorption to host cells, a latent period of approximately 60 min, and a burst size of 82 ± 14 PFU per infected cell. Lucjan infected 42% of tested clinical isolates and significantly reduced established P. aeruginosa biofilms in vitro. Combined treatment with selected antibiotics resulted in enhanced suppression of bacterial growth compared with single-agent exposure. Together, these findings position Lucjan as a genomically safe and functionally active representative of the Abidjanvirus lineage and highlight the potential of environmentally derived lytic phages as candidates for further evaluation in combinatorial antimicrobial strategies.
Indexed as
Identifiers
41805923What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.